Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial
Rossella Di Franco, Simona Mercogliano, Rocco Mottareale, Valentina Borzillo et autres
0 citationsFuture Oncology
Sandro Pignata
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
901Publications signalées
36991Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyEndometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersBRCA gene mutations in cancer
Publications récentes
Somatic BRCA1 and BRCA2 detection in homologous recombination deficiency testing: concordance of four sequencing workflows with the Myriad myChoice companion diagnostic
Giovanni Luca Scaglione, Cristin Roma, Daniela Califano, Sabrina Chiara Cecere et autres
0 citationsInternational Journal of Gynecological Cancer
PIK3CA mutations in advanced or recurrent endometrial cancer: an exploratory molecular profiling from the phase II MITO END-3 study. A pre-planned translational molecular analysis on PIK3CA mutational status.
Sandro Pignata, Anna Passarelli
0 citationsZenodo (CERN European Organization for Nuclear Research)
PIK3CA mutations in advanced or recurrent endometrial cancer: an exploratory molecular profiling from the phase II MITO END-3 study. A pre-planned translational molecular analysis on PIK3CA mutational status.
Sandro Pignata, Anna Passarelli
0 citationsZenodo (CERN European Organization for Nuclear Research)
48P Surveillance strategy is safe in stage I dysgerminomas: results from the MITO-9
M.V. Luciani, Robert Fruscio, Gennaro Cormio, A. Fagotti et autres
0 citationsESMO rare cancers.
Particle Beam Re-irradiation in Oligo Recurrent Gynecological Malignancies
Amelia Barcellini, Alessandro Vai, Giulia Fontana, Chiara Cassani et autres
1 citationClinical Oncology
Cross-platform benchmarking of somatic BRCA1/2 detection: four HRD NGS workflows against the Myriad MyChoice CDx reference assay
0 citationsZenodo (CERN European Organization for Nuclear Research)
Cross-platform benchmarking of somatic BRCA1/2 detection: four HRD NGS workflows against the Myriad MyChoice CDx reference assay
0 citationsZenodo (CERN European Organization for Nuclear Research)
Surgical timing in advanced ovarian cancer during the TRUST trial era: A systematic review, meta-analysis and study-level meta-regression of randomized controlled trials
Veronica Tius, Cristina Taliento, Martina Arcieri, S Filippin et autres
3 citationsEuropean Journal of Surgical Oncology
663TiP BNT323-01: A phase III trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)
J-H. Kim, Hanna Dahlstrand, P-H. Wang, K.N. Moore et autres
0 citationsAnnals of Oncology
604MO Prognostic value of progression free status at 6 months on overall survival (OS) in platinum resistant ovarian cancer (PROC): Landmark analysis from the GCIG Symptom Benefit Study
Omali Pitiyarachchi, C. Lee, H-W. Sim, R. Oconnell et autres
0 citationsAnnals of Oncology
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective
Anna Passarelli, Sabrina Chiara Cecere, Jole Ventriglia, Carmela Pisano et autres
5 citationsFrontiers in Immunology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.